| Description |
1 online resource |
| Bibliography |
Includes bibliographical references and index. |
| Contents |
A new type of blockbuster : the growth of biologics -- Déjá vu or something new? : comparing the generics and biosimilars experiences -- Bugs and drugs, and yeast and mice, and Chinese hamsters -- The $250 billion pyramid : analytics in biosimilarity determination -- The global biosimilars experience -- The American biosimilar experience : red, white, and possibly interchangeable -- Biosimilar clinical trial requirements -- Immunogenicity and pharmacovigilance in the biosimilar era -- The patent dance and the exclusivity shuffle -- Defining biosimilar value and other impossible tasks -- Biosimilar formulary management strategies. |
| Note |
Online resource; title from PDF title page (EBSCO, viewed August 8, 2018). |
| Summary |
Get Up to Speed on the Fastest Growing Pharmaceutical Innovation With the Only Guide Written for Pharmacists Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars, are finally beginning to exert a greater impact on practice. To meet the growing need for information, ASHP has published Biosimilars and Biologics. This authoritative, evidence-based resource provides an in-depth perspective on all areas related to these innovative drugs, including: · Legislative/regulatory issues, including the biosimilars act and anticipated FDA guidelines · |
| Subject |
Pharmaceutical biotechnology.
|
|
Pharmaceutical biotechnology industry.
|
|
Drugs -- Generic substitution.
|
|
Pharmaceutical policy.
|
|
Biological products.
|
|
MEDICAL -- Pharmacology.
|
|
Biological products. (OCoLC)fst00832292
|
|
Drugs -- Generic substitution.
(OCoLC)fst00898814
|
|
Pharmaceutical biotechnology. (OCoLC)fst01060106
|
|
Pharmaceutical biotechnology industry. (OCoLC)fst01060113
|
|
Pharmaceutical policy. (OCoLC)fst01060194
|
| ISBN |
9781585285815 (electronic bk.) |
|
1585285811 (electronic bk.) |
|
9781585285808 |
|
1585285803 |
|
